24/4/22
Applications open
Roche & Start-Up Nation Central share the vision of enhanced digital health support for Alzheimer’s disease patients and their caregivers. We strive to identify innovative solutions that will make a difference in patients’ lives, enabling prevention, early detection, intervention & monitoring. This is why we founded the “Roche for a better future: Alzheimer’s Innovation Challenge”
Please note: Applications are now closed.
Relevant solutions have applied to the Roche Alzheimer’s Innovation Challenge, ranging from early detection, brain health, monitoring, disease management and support for caregivers.
startups made it to the global showcase event
Neurosteer’s non-invasive brain-monitoring solution for early detection of Parkinson’s, Alzheimer’s, and other neurological disorders consists of an inexpensive medical-grade wearable device and cloud-based system, provides objective biomarkers and remote real-time assessment of brain activity, and is suitable for mass deployment.
Sensi is an AI-based solution for home care agencies and elder care communities. Sensi provides audio analytics-based insight that helps not only eliminate blind-spots, but also predict and prevent unwanted events from occurring. Sensi’s mission is to enable older adults to age with the respect, confidence and dignity that they deserve.
Shomerosh is a digital data-based tool for early prediction and prevention of Alzheimer’s disease. It combines a novel cognitive assessment with personalized preventive recommendations, and enables a long follow-up with a simple, user-friendly and self-administered app.
Brain Network Analysis (BNA) objectively measures a patient’s brain activity in a non-invasive way by using a medical-grade EEG. Our cloud-based AI Algorithm automatically identifies the unique brain patterns of the patient and compares them to an age-matched normative group.
Montfort Brain Monitor (Mon4t) app turns daily life smartphones into medical device, enabling continuous and objective neurological assessment from the comfort of patient’s home. Finally, neurologists can use data to support their clinical decisions, optimize treatment and get alerts for anomalies & deterioration. Mon4t’s digital markers also accelerate drug development and clinical research.
Alzheimer’s disease (AD) is the most common form of dementia, a term used to describe different brain disorders that affect memory, thinking, behavior and emotion. There are currently estimated to be over 55 million people worldwide living with dementia with significant social and economic consequences.
There is a growing recognition that the process of Alzheimer’s disease begins many years prior to clinically obvious symptoms. Thus the ultimate goal of identifying individuals in the preclinical stages of Alzheimer disease with less invasive, faster and more effective methods, is to facilitate early intervention to delay the clinical syndrome, promote early and optimal management, optimize physical health, cognition, activity and wellbeing.
Ideal functionality:
*You may apply even if your solution does not meet all these functions
Should be self-administered by individuals ideally in the remote environment (e.g. at home). Ready to market solution – an advantage
The solution should be non-invasive
The solution ideally provides advanced analytics calculating a risk score for diagnosis/monitoring
Is ideally based on a daily life device (e.g. smartphone), and does not require proprietary hardware
Advantage: the solution interfaces with and can be connected to medical information systems via FHIR standards.
Roche is a global pioneer in pharmaceuticals and diagnostics and the world’s largest biotech company, focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalized healthcare.
In Roche, innovation has always been about identifying and seizing opportunities. Despite the great medical progress, there is still a huge need and a growing demand for specific diagnostics and better tolerated therapies. Going forward, Roche intends to again increase its investment in research and development.
For more information, please visit www.roche.com
Start-Up Nation Central is the address for corporations, governments and investors to connect with the Israeli tech ecosystem. We catalyze growth opportunities by bringing Israeli tech innovation to global business and societal challenges. Established in 2013 and headquartered in Tel-Aviv, Israel, Start-Up Nation Central is a not-for-profit organization funded by philanthropy.
For more information, please visit www.startupnationcentral.org
RoX Health is a Startup Studio rooted in Roche, based in Berlin, Germany. We turn ideas into healthcare businesses and encourage greater initiative in the healthcare industry. Currently, we focus on certain topics in oncology, neurology and women’s health
For more information, please visit https://roxhealth.com